Prognosis of impulse control disorders in Parkinson's disease: a prospective controlled study.
Cognition
Dopaminergic agonists
Impulse control disorders
Parkinson’s disease
Prognosis
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
12 Jan 2024
12 Jan 2024
Historique:
received:
23
08
2023
accepted:
23
12
2023
revised:
21
12
2023
medline:
12
1
2024
pubmed:
12
1
2024
entrez:
12
1
2024
Statut:
aheadofprint
Résumé
The long-term prognosis of impulsive compulsive disorders (ICD) remains poorly studied in Parkinson's disease (PD). Evaluating the natural history of ICD and its impact on PD symptoms including cognition and treatment adjustments. We assessed PD patients at baseline (BL) with (BL-ICD+) or without (BL-ICD-) ICD despite dopamine agonist (DA) exposure of > 300 mg levodopa-equivalent daily dose for > 12 months at baseline and after more than two years of follow-up. ICD were assessed using the Ardouin's Scale of Behaviors in PD (ASBPD), cognition using the Mattis scale, and PD symptoms using the UPDRS score. Treatment adjustments, DA withdrawal-associated symptoms, and ICDs social consequences were recorded. 149 patients were included (78 cases and 71 controls), mean duration of follow-up was 4.4 ± 1 years. At baseline, psychiatric disorders were more common among BL-ICD + (42.3 vs 12.3% among BL-ICD-, p < 0.01). At follow-up, 53.8% of BL-ICD + were not ICD-free while 21.1% of BL-ICD- had developed ICD. BL-ICD + more frequently experienced akinesia (21.8 vs 8.5%, p = 0.043) and rigidity worsening (11.5 vs 1.4%, p = 0.019) following therapeutic modifications. Decision to decrease > 50% DA doses (12.8 vs 1.4%, p = 0.019) or to withdraw DA (19.2 vs 5.6%, p = 0.025) was more frequently considered among BL-ICD+ . At follow-up, the prevalence of cognitive decline was lower among BL-ICD + (19.2 vs 37.1%, p = 0.025). ICDs were associated with increased psychiatric burden at baseline and better cognitive prognosis. Most patients were still showing ICDs at the follow-up visit, suggesting ICD to be considered as a chronic, neuropsychiatric disorder.
Sections du résumé
BACKGROUND
BACKGROUND
The long-term prognosis of impulsive compulsive disorders (ICD) remains poorly studied in Parkinson's disease (PD).
OBJECTIVE
OBJECTIVE
Evaluating the natural history of ICD and its impact on PD symptoms including cognition and treatment adjustments.
MATERIALS AND METHODS
METHODS
We assessed PD patients at baseline (BL) with (BL-ICD+) or without (BL-ICD-) ICD despite dopamine agonist (DA) exposure of > 300 mg levodopa-equivalent daily dose for > 12 months at baseline and after more than two years of follow-up. ICD were assessed using the Ardouin's Scale of Behaviors in PD (ASBPD), cognition using the Mattis scale, and PD symptoms using the UPDRS score. Treatment adjustments, DA withdrawal-associated symptoms, and ICDs social consequences were recorded.
RESULTS
RESULTS
149 patients were included (78 cases and 71 controls), mean duration of follow-up was 4.4 ± 1 years. At baseline, psychiatric disorders were more common among BL-ICD + (42.3 vs 12.3% among BL-ICD-, p < 0.01). At follow-up, 53.8% of BL-ICD + were not ICD-free while 21.1% of BL-ICD- had developed ICD. BL-ICD + more frequently experienced akinesia (21.8 vs 8.5%, p = 0.043) and rigidity worsening (11.5 vs 1.4%, p = 0.019) following therapeutic modifications. Decision to decrease > 50% DA doses (12.8 vs 1.4%, p = 0.019) or to withdraw DA (19.2 vs 5.6%, p = 0.025) was more frequently considered among BL-ICD+ . At follow-up, the prevalence of cognitive decline was lower among BL-ICD + (19.2 vs 37.1%, p = 0.025).
CONCLUSION
CONCLUSIONS
ICDs were associated with increased psychiatric burden at baseline and better cognitive prognosis. Most patients were still showing ICDs at the follow-up visit, suggesting ICD to be considered as a chronic, neuropsychiatric disorder.
Identifiants
pubmed: 38214756
doi: 10.1007/s00415-023-12170-7
pii: 10.1007/s00415-023-12170-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Potenza MN, Voon V, Weintraub D (2007) Drug Insight: impulse control disorders and dopamine therapies in Parkinson’s disease. Nat Rev Neurol 3:664–672
doi: 10.1038/ncpneuro0680
Weintraub D, Mamikonyan E (2019) Impulse control disorders in Parkinson’s disease. AJP 176:5–11
doi: 10.1176/appi.ajp.2018.18040465
Voon V, Napier TC, Frank MJ et al (2017) Impulse control disorders and levodopa-induced dyskinesias in Parkinson’s disease: an update. Lancet Neurol 16:238–250
doi: 10.1016/S1474-4422(17)30004-2
pubmed: 28229895
Santangelo G, Barone P, Trojano L et al (2013) Pathological gambling in Parkinson’s disease. A comprehensive review. Parkinsonism Relat Disord 19:645–53
doi: 10.1016/j.parkreldis.2013.02.007
pubmed: 23490464
Nirenberg MJ, Waters C (2006) Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 21:524–529
doi: 10.1002/mds.20757
pubmed: 16261618
Nakum S, Cavanna AE (2016) The prevalence and clinical characteristics of hypersexuality in patients with Parkinson’s disease following dopaminergic therapy: a systematic literature review. Parkinsonism Relat Disord 25:10–16
doi: 10.1016/j.parkreldis.2016.02.017
pubmed: 26923525
Weintraub D, Claassen DO (2017) Impulse Control and Related Disorders in Parkinson’s Disease. Int Rev Neurobiol 133:679–717
doi: 10.1016/bs.irn.2017.04.006
pubmed: 28802938
Faouzi J, Corvol J-C, Mariani L-L (2021) Impulse control disorders and related behaviors in Parkinson’s disease: risk factors, clinical and genetic aspects, and management. Curr Opin Neurol 34:547–555
doi: 10.1097/WCO.0000000000000955
pubmed: 33967198
Kelly MJ, Baig F, Hu MT-M et al (2020) Spectrum of impulse control behaviours in Parkinson’s disease: pathophysiology and management. J Neurol Neurosurg Psychiatry 91:703–11
doi: 10.1136/jnnp-2019-322453
pubmed: 32354771
Weintraub D, Koester J, Potenza MN et al (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589–595
doi: 10.1001/archneurol.2010.65
pubmed: 20457959
Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A et al (2014) Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry 85:840–844
doi: 10.1136/jnnp-2013-306787
pubmed: 24434037
Corvol J-C, Artaud F, Cormier-Dequaire F et al (2018) Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 91:e189-201
doi: 10.1212/WNL.0000000000005816
pubmed: 29925549
pmcid: 6059034
Siri C, Cilia R, Reali E et al (2015) Long-term cognitive follow-up of Parkinson’s disease patients with impulse control disorders. Mov Disord 30:696–704
doi: 10.1002/mds.26160
pubmed: 25757654
Mamikonyan E, Siderowf AD, Duda JE et al (2008) Long-term follow-up of impulse control disorders in Parkinson’s disease. Mov Disord 23:75–80
doi: 10.1002/mds.21770
pubmed: 17960796
pmcid: 2651355
Bastiaens J, Dorfman BJ, Christos PJ et al (2013) Prospective cohort study of impulse control disorders in Parkinson’s disease. Mov Disord 28:327–333
doi: 10.1002/mds.25291
pubmed: 23283708
pmcid: 3894820
Averbeck BB, O’Sullivan SS, Djamshidian A (2014) Impulsive and compulsive behaviors in Parkinson’s disease. Annu Rev Clin Psychol 10:553–580
doi: 10.1146/annurev-clinpsy-032813-153705
pubmed: 24313567
Cormier-Dequaire F, Bekadar S, Anheim M et al (2018) Suggestive association between OPRM1 and impulse control disorders in Parkinson’s disease. Mov Disord 33:1878–1886
doi: 10.1002/mds.27519
pubmed: 30444952
Tomlinson CL, Stowe R, Patel S et al (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653
doi: 10.1002/mds.23429
pubmed: 21069833
Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129–2170
doi: 10.1002/mds.22340
pubmed: 19025984
Schmidt R, Freidl W, Fazekas F et al (1994) The Mattis dementia rating scale: normative data from 1,001 healthy volunteers. Neurology 44:964–964
doi: 10.1212/WNL.44.5.964
pubmed: 8190307
Dubois B, Burn D, Goetz C et al (2007) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314–2324
doi: 10.1002/mds.21844
pubmed: 18098298
Ardouin C, Chéreau I, Llorca P-M et al (2009) Assessment of hyper- and hypodopaminergic behaviors in Parkinson’s disease. Rev Neurol (Paris) 165:845–856
doi: 10.1016/j.neurol.2009.06.003
pubmed: 19683776
Weiss HD, Marsh L (2012) Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease. Neurol Clin Pract 2:267–274
doi: 10.1212/CPJ.0b013e318278be9b
pubmed: 23634371
pmcid: 3613210
Nirenberg MJ (2013) Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging 30:587–592
doi: 10.1007/s40266-013-0090-z
pubmed: 23686524
Grant JE, Odlaug BL, Chamberlain SR et al (2013) A proof of concept study of tolcapone for pathological gambling: relationships with COMT genotype and brain activation. Eur Neuropsychopharmacol 23:1587–1596
doi: 10.1016/j.euroneuro.2013.07.008
pubmed: 23953269
Kurtis MM, Rajah T, Delgado LF et al (2017) The effect of deep brain stimulation on the non-motor symptoms of Parkinson’s disease: a critical review of the current evidence. npj Parkinson’s Dis 3:1–12
deS Santin MN, Voulleminot P, Vrillon A et al (2021) Impact of subthalamic deep brain stimulation on impulse control disorders in Parkinson’s disease: a prospective study. Mov Disord. 36:750–7
doi: 10.1002/mds.28320
pubmed: 33022101
Liang J, Groves M, Shanker VL (2015) Clozapine treatment for impulse control disorders in Parkinson’s disease patients: a case series. Mov Disord Clin Pract 2:283–285
doi: 10.1002/mdc3.12167
pubmed: 30363600
pmcid: 6178770
Béreau M, Van Waes V, Servant M et al (2023) Apathy in Parkinson’s disease: clinical patterns and neurobiological basis. Cells 12:1599
doi: 10.3390/cells12121599
pubmed: 37371068
pmcid: 10297386
Scott BM, Eisinger RS, Burns MR et al (2020) Co-occurrence of apathy and impulse control disorders in Parkinson disease. Neurology 95:e2769–e2780
doi: 10.1212/WNL.0000000000010965
pubmed: 33004605
pmcid: 7734726
Sierra M, Carnicella S, Strafella AP et al (2015) Apathy and impulse control disorders: Yin & Yang of dopamine dependent behaviors. J Parkinsons Dis 5:625–636
doi: 10.3233/JPD-150535
pubmed: 25870025
Marín-Lahoz J, Sampedro F, Martinez-Horta S et al (2019) Depression as a risk factor for impulse control disorders in Parkinson disease. Ann Neurol 86:762–769
doi: 10.1002/ana.25581
pubmed: 31415102
Aarsland D, Påhlhagen S, Ballard CG et al (2011) Depression in Parkinson disease–epidemiology, mechanisms and management. Nat Rev Neurol 8:35–47
doi: 10.1038/nrneurol.2011.189
pubmed: 22198405
Aracil-Bolaños I, Strafella AP (2016) Molecular imaging and neural networks in impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord 22(Suppl 1):S101-105
doi: 10.1016/j.parkreldis.2015.08.003
pubmed: 26298389
Cowen PJ (2008) Serotonin and depression: pathophysiological mechanism or marketing myth? Trends Pharmacol Sci 29:433–436
doi: 10.1016/j.tips.2008.05.004
pubmed: 18585794
Kraemmer J, Smith K, Weintraub D et al (2016) Clinical-genetic model predicts incident impulse control disorders in Parkinson’s disease. J Neurol Neurosurg Psychiatry 87:1106–1111
doi: 10.1136/jnnp-2015-312848
pubmed: 27076492
Zhi Y, Yuan Y, Si Q et al (2019) The association between DRD3 Ser9Gly polymorphism and depression severity in Parkinson’s disease. Parkinson’s Dis 2019:e1642087
Peciña M, Karp JF, Mathew S et al (2019) Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Mol Psychiatry 24:576–587
doi: 10.1038/s41380-018-0117-2
pubmed: 29955162